CARBOPLATIN, EPIRUBICIN, AND VP-16 CHEMOTHERAPY IN THE TREATMENT OF SMALL-CELL LUNG-CANCER

被引：8

作者：

GRIDELLI, C ^{[1
]}

IANNIELLO, GP ^{[1
]}

MAIORINO, A ^{[1
]}

CURCIO, C ^{[1
]}

DAPRILE, M ^{[1
]}

BRANCACCIO, L ^{[1
]}

PALMERI, S ^{[1
]}

GENTILE, M ^{[1
]}

COMELLA, G ^{[1
]}

PEDICINI, T ^{[1
]}

AIROMA, G ^{[1
]}

VELTRI, E ^{[1
]}

GEBBIA, V ^{[1
]}

RUSSO, A ^{[1
]}

CASARETTI, R ^{[1
]}

GIAMPAGLIA, F ^{[1
]}

FERRANTE, G ^{[1
]}

RAUSA, L ^{[1
]}

IACOBELLI, S ^{[1
]}

ARCANGELI, G ^{[1
]}

DEPLACIDO, S ^{[1
]}

BIANCO, AR ^{[1
]}

机构：

[1] UNIV NAPLES,FAC MED & CHIRURG 2,CATTERA ONCOL MED,INTERREG STUDIO NEOPLASIE POLMONARI GRP,I-80131 NAPLES,ITALY

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1994年 / 17卷 / 02期

关键词：

SMALL CELL LUNG CANCER; CHEMOTHERAPY;

D O I：

10.1097/00000421-199404000-00014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent ''split-course'' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.

引用

页码：160 / 167

页数：8

共 13 条

[1] CARBOPLATIN (CBDCA, JM-8) AND VP-16-213 IN PREVIOUSLY UNTREATED PATIENTS WITH SMALL-CELL LUNG-CANCER [J].

BISHOP, JF ;

RAGHAVAN, D ;

STUARTHARRIS, R ;

MORSTYN, G ;

ARONEY, R ;

KEFFORD, R ;

YUEN, K ;

LEE, J ;

GIANOUTSOS, P ;

OLVER, IN ;

ZALCBERG, J ;

BALL, D ;

BULL, C ;

FOX, R .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1574-1578

[2] EPIRUBICIN IN EXTENSIVE SMALL-CELL LUNG-CANCER - A PHASE-II STUDY IN PREVIOUSLY UNTREATED PATIENTS - A NATIONAL CANCER INSTITUTE OF CANADA CLINICAL-TRIALS GROUP-STUDY [J].

BLACKSTEIN, M ;

EISENHAUER, EA ;

WIERZBICKI, R ;

YOSHIDA, S .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :385-389

[3]

CRINO L, 1991, LUNG CANCER S, V7, P161

[4] VP-16 AND CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH EXTENSIVE SMALL CELL LUNG-CANCER - A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL-TRIALS GROUP [J].

EVANS, WK ;

EISENHAUER, E ;

HUGHES, P ;

MAROUN, JA ;

AYOUB, J ;

SHEPHERD, FA ;

FELD, R .

BRITISH JOURNAL OF CANCER, 1988, 58 (04) :464-468

[5]

GATZMEIER U, 1989, P AM SOC CLIN ONCOL, V8, P230

[6]

HUMBLET Y, 1989, MED ONCOL TUMOR PHAR, V6, P207

[7]

JACOBS RH, 1987, CANCER TREAT REP, V71, P311

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[10]

2-6

← 1 2 →